Department of Pediatric Cardiology, University of Health Sciences, Konya Training and Research Hospital, Konya, Turkey.
Department of Pediatric Endocrinology, Konya Training and Research Hospital, Konya, Turkey.
Endocrine. 2019 Sep;65(3):601-607. doi: 10.1007/s12020-019-01933-w. Epub 2019 Apr 19.
Subclinical hypothyroidism, defined as increased TSH serum levels and normal serum free T4 concentrations, has been associated with an increased risk of heart disease in adults. But, data in children and adolescents are scanty and treatment of subclinical hypothyroidism is controversial. Growth differentiation factor-15 (GDF-15) is a promising biomarker of cardiac remodeling. This study aimed to evaluate the cardiovascular risk factors in children with subclinical hypothyroidism, measured with tissue Doppler echocardiography (TDE), and conventional echocardiography and GDF-15 level.
The study comprised a total of 41 pediatric patients with subclinical hypothyroidism (SH) (mean age 9.6 ± 4.7 years) and 31 healthy children (mean age 11.2 ± 3.4 years) as the control group. Subclinical hypothyroidism was defined as a thyroid-stimulating hormone level higher than 4 mIU/l and a normal free-thyroxine level (0.6-1.8 ng/dl). Tissue Doppler echocardiography was performed to all individuals in the control group and patient group at the beginning of the study. Global systolic function as assessed by left ventricular ejection fraction was compared between groups. The serum GDF-15 level was measured.
There were no significant differences in demographic parameters between the SH and control groups. The left ventricular internal diameter end systole, interventricular septal end diastole, left ventricular posterior wall end diastole, and tricuspid annular plane systolic excursion values were significantly different between the SH and control groups (p = 0.038, 0.028, 0.005, and 0.000, respectively). The mean mitral isovolumic relaxation time value of the SH group was 57.2 ± 9.3 ms, compared to 44.5 ± 5.6 ms for the control group (p = 0.000). The mean tricuspid isovolumic contraction time value of the SH group was 58.7 ± 9.4 ms, and that of the control group was 45.1 ± 5.3 ms (p = 0.000). The mean tricuspid isovolumic relaxation time value of the SH group was 58.03 ± 9.5 ms, and that of the control group was 45.1 ± 5.3 ms (p = 0.000). There were no significant differences in the other m-mode or pulse Doppler echocardiography values between two groups. The GDF-15 value of the SH group was 382.6 ± 268.2 pg/mL, and that of the control group was 473.6 ± 337.9 pg/mL; this difference was not significant.
Patients with subclinical hypothyroidism versus healthy individuals had some changes in echocardiographic parameters that indicate involvement of diastolic function of the left ventricle. They were significantly different when compared SH group and the control group. This study demonstrated ventricle diastolic dysfunction in pediatric patients with hypothyroidism. The results of our study suggest that cardiac follow-up may be useful in patients with subclinical hypothyroidism and clinical trials are needed to explore therapeutic effects of T4 and T3 administration in this patients.
促甲状腺激素(TSH)血清水平升高而游离甲状腺素(FT4)浓度正常的亚临床甲状腺功能减退症与成人心脏病风险增加有关。然而,儿童和青少年的数据较少,亚临床甲状腺功能减退症的治疗存在争议。生长分化因子-15(GDF-15)是心脏重构的一个有前途的生物标志物。本研究旨在通过组织多普勒超声心动图(TDE)和常规超声心动图评估亚临床甲状腺功能减退症儿童的心血管危险因素,并检测 GDF-15 水平。
本研究共纳入 41 例亚临床甲状腺功能减退症(SH)患儿(平均年龄 9.6±4.7 岁)和 31 名健康儿童(平均年龄 11.2±3.4 岁)作为对照组。亚临床甲状腺功能减退症定义为 TSH 水平高于 4mIU/L,游离甲状腺素水平正常(0.6-1.8ng/dl)。所有对照组和患者组在研究开始时均进行 TDE 检查。比较两组左心室射血分数的整体收缩功能。测量血清 GDF-15 水平。
SH 组和对照组之间在人口统计学参数方面无显著差异。左心室收缩末期内径、室间隔舒张末期内径、左心室后壁舒张末期内径和三尖瓣环平面收缩期位移值在 SH 组和对照组之间有显著差异(p=0.038、0.028、0.005 和 0.000)。SH 组平均二尖瓣等容舒张时间值为 57.2±9.3ms,对照组为 44.5±5.6ms(p=0.000)。SH 组平均三尖瓣等容收缩时间值为 58.7±9.4ms,对照组为 45.1±5.3ms(p=0.000)。SH 组平均三尖瓣等容舒张时间值为 58.03±9.5ms,对照组为 45.1±5.3ms(p=0.000)。两组间其他 M 模式或脉冲多普勒超声心动图值无显著差异。SH 组的 GDF-15 值为 382.6±268.2pg/ml,对照组为 473.6±337.9pg/ml;但差异无统计学意义。
与健康个体相比,亚临床甲状腺功能减退症患者的超声心动图参数发生了一些变化,提示左心室舒张功能受累。与 SH 组和对照组相比,这些差异具有统计学意义。本研究表明,甲状腺功能减退症患儿存在心室舒张功能障碍。我们的研究结果表明,对亚临床甲状腺功能减退症患者进行心脏随访可能是有用的,需要进行临床试验以探讨 T4 和 T3 给药在这些患者中的治疗效果。